Therefore, these results suggest that BSE pretreatment may help reduce the risk of acute gastritis by inhibiting the NF-κB signaling pathway, which is activated during acute gastritis, and by inducing the production of PGE2, a regulator of immune and inflammatory responses, thereby suppressing inflammatory cytokines such as TNF-α and IL-1β. The gene discussed is NFKB1; the disease is gastritis.